GlassScriptPhysician profile
Ashley E Banda
NPI 1467762773
$2,712.67
in general payments reported to CMS, 2019-2025
27 companies · $966 in 2025
The $966 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $225 · 2023: $510 · 2024: $747 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.17 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $361.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.82 | 2021-2025 | Jardiance |
| Amgen INC. | $222.46 | 2023-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $203.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $199.69 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $190.02 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $168.23 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $144.06 | 2021-2025 | |
| Astellas Pharma US INC | $129.80 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $126.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $103.08 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $65.52 | 2023-2024 | |
| Avvisto Therapeutics, LLC | $64.67 | 2025 | Cycloset |
| Dexcom, INC. | $61.31 | 2024-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $59.26 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $50.98 | 2024-2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $47.92 | 2021-2022 | |
| Mannkind Corporation | $42.50 | 2025 | |
| Xeris Pharmaceuticals, INC. | $34.41 | 2022 | |
| Merck Sharp & Dohme LLC | $31.26 | 2021-2025 | Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $24.78 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $23.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.88 | 2023 | Xarelto |
| Insulet Corporation | $16.68 | 2023 | Omnipod |
| Biogen, INC. | $16.41 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.68 | 2023 | Cycloset |
| Nestle Healthcare Nutrition INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Banda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.